Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

Talaris Therapeutics logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Key Stats

Today's Range
$47.66
$47.72
50-Day Range
$12.36
$28.36
52-Week Range
$0.89
$27.95
Volume
750,112 shs
Average Volume
386,531 shs
Market Capitalization
$2.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TALS Stock News Headlines

Tourmaline Bio, Inc. (TRML)
REVEALED: Something Big Happening Behind White House Doors
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Longitude Venture Partners III, L.P.'s Net Worth
See More Headlines

TALS Stock Analysis - Frequently Asked Questions

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its earnings results on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03.

Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

Last Earnings
11/12/2021
Today
9/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CIK
1827506
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.89 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
11.02

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$2.04 billion
Optionable
Not Optionable
Beta
2.18

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:TALS) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners